Tina Wu

Associate

tina-wu
  • LLM, Columbia Law School, 2014
  • LLM, Peking University Law School, 2008
  • BA, China Pharmaceutical University, 2005

Qualifications

  • New York, 2014
  • Chinese (Mandarin)

Tina Wu

Associate

View the Chinese version.

Tina Wu is an associate in our life sciences group.  She has extensive experience in advising pharmaceutical, biotechnology, medical device and healthcare clients on a wide variety of matters arising from the entire product life cycle, including regulatory issues concerning clinical and non-clinical research, data privacy, digital health, product development and market access strategies, M&A, collaboration, partnership and licensing deals, post-market compliance and enforcement actions, telemedicine and healthcare services.

Prior to joining Ropes & Gray, she worked at a leading international law firm, advising multi-national companies on regulatory, intellectual property and compliance matters, with a particular focus on the healthcare and life science industry.

She passed the PRC Bar Exam in 2006 and the New York State Bar Exam in 2014.

Experience

  • Assisted a leading US pharmaceutical company with the divestiture of certain business units in China, and provided legal advice on relevant pharmaceutical regulatory matters.
  • Assisted multiple innovative biopharmaceutical companies with the transaction in connection with collaboration development, licensing and product localization arrangements, and provided legal advice on relevant regulatory matters.
  • Assisted a venture fund with its investment in a PRC pharmaceutical company to assess the product portfolio and regulatory risks. 
  • Advised a leading US pharmaceutical company on its drug development collaboration with a China based CAR-T Biotech Company, and provided legal advice on relevant pharmaceutical regulatory affairs.
  • Assisted a world leading biopharmaceutical company in regulatory due diligence in relation to its collaboration with a Chinese partner for developing and commercializing its biological products in China.
  • Assisted a PRC pharmaceutical company with the acquisition of foreign generic drug business, and provided legal advice on relevant pharmaceutical regulatory matters.
  • Advised multinational pharmaceutical companies and investment companies on the collection, use, transfer and cross-border transfer of healthcare data and patient data.  
  • Assisted a private equity firm in data compliance due diligence on a leading oncology big data company in China.
  • Advised numerous multinational pharmaceutical and medical device companies on their clinical and non-clinical research projects involving use of Chinese human genetic resources and biological samples.
  • Assisted a leading US medical devices company with M&A transactions in connection with PRC-related products, and provided legal advice on relevant regulatory affairs.
  • Advised several renowned US medical centers on the feasibility and legal risks of telemedicine services targeted toward PRC patients.
  • Advised several leading medical devices companies on potential business models and implications under the Market Authorization Holder system.  
  • Advised a leading US medical devices company on the marketing model and legal risks associated with the two-invoice system and other matters.
  • Advised a leading US medical devices company on post-market surveillance of its products, including its strategies of communication with law enforcement agencies and legal risks associated with relevant matters.

Publications

  • LLM, Columbia Law School, 2014
  • LLM, Peking University Law School, 2008
  • BA, China Pharmaceutical University, 2005
Cookie Settings